Shares of drug firm Ind Swift Laboratories shot up by over 3% on the BSE today after the company said its shareholders have approved raising up to Rs 500 crore through the issue of securities.
After a positive opening, shares of the company jumped further by 3.58% to touch a high of Rs 86.75 on the BSE.
Shareholders of the company have approved raising up to Rs 500 crore through the issue of global depositary receipts (GDRs), foreign currency convertible bonds (FCCBs) and convertible bonds, Ind Swift Laboratories has said in a regulatory filing.
However, the company did not provide a timeline for raising the funds.
The announcement was made after the market close yesterday.
The surge in the stock was in sync with the overall bullish trend in the stock market, with the BSE benchmark Sensex trading 1.76% higher at 16,334.25 at 1035 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app